# Invivyd (IVVD.US)

Canonical: https://gigainvestors.com/s/IVVD

Analysis as of: 2026-10-16T07:29:26.987Z. 

Listing currency: USD. Reporting currency: USD.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: fail; earnings resilience is evidence only). Published buy qualification: no.

Share price: $0.67 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

- [Lee Ainslie](https://gigainvestors.com/mc): tracked 13F investor; follow the investor page for holding quarter and amounts.

## Price story

Down 99% since Nov 2021

Story as of 2026-10-16T10:01:29.700Z; price observation 2026-10-15.

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in biotechnology; annual sales are USD 53.4 million.

- Source: https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm (filed 2026-03-05); FY2025: revenue 53426000; grossProfit 49679000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-05); IVVD.US: Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in  pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.

### Where the cash goes

Paid no dividends in 5 years; bought back USD 633000 of shares.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-05); Dividend observations: [[2021,0],[2022,0],[2023,0],[2024,0],[2025,0]]. Zero only counted when supported by a complete cash-flow statement.

- Source: https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm (filed 2026-03-05); FY2025: cash repurchases 633000 USD.

### What the price says

The price is 2.2 times annual sales; cash earnings are negative.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-03-05); Closing price 0.6688 USD; reporting-to-trading FX 1; FY2025 annual sales per share 0.3102322728409745; price multiple 2.1558040814884136. FY2025 cash earnings/share -0.29345652627118496. Closing-price date 2026-10-15.

## Monthly share-price history (USD per share)

- 2021-08: $33.84 per share

- 2021-09: $42.24 per share

- 2021-10: $29.24 per share

- 2021-11: $47.04 per share

- 2021-12: $7.26 per share

- 2022-01: $7.18 per share

- 2022-02: $6.69 per share

- 2022-03: $4.56 per share

- 2022-04: $2.86 per share

- 2022-05: $2.96 per share

- 2022-06: $3.28 per share

- 2022-07: $3.52 per share

- 2022-08: $4.56 per share

- 2022-09: $3.13 per share

- 2022-10: $3.95 per share

- 2022-11: $2.26 per share

- 2022-12: $1.50 per share

- 2023-01: $2.28 per share

- 2023-02: $1.74 per share

- 2023-03: $1.20 per share

- 2023-04: $1.10 per share

- 2023-05: $1.80 per share

- 2023-06: $1.05 per share

- 2023-07: $1.48 per share

- 2023-08: $1.86 per share

- 2023-09: $1.70 per share

- 2023-10: $1.58 per share

- 2023-11: $1.53 per share

- 2023-12: $3.94 per share

- 2024-01: $4.77 per share

- 2024-02: $3.93 per share

- 2024-03: $4.44 per share

- 2024-04: $2.22 per share

- 2024-05: $1.84 per share

- 2024-06: $1.10 per share

- 2024-07: $1.25 per share

- 2024-08: $0.85 per share

- 2024-09: $1.02 per share

- 2024-10: $0.89 per share

- 2024-11: $0.70 per share

- 2024-12: $0.44 per share

- 2025-01: $0.36 per share

- 2025-02: $1.16 per share

- 2025-03: $0.61 per share

- 2025-04: $0.63 per share

- 2025-05: $0.94 per share

- 2025-06: $0.72 per share

- 2025-07: $0.69 per share

- 2025-08: $0.97 per share

- 2025-09: $1.10 per share

- 2025-10: $1.76 per share

- 2025-11: $2.43 per share

- 2025-12: $2.47 per share

- 2026-01: $1.74 per share

- 2026-02: $1.69 per share

- 2026-03: $1.30 per share

- 2026-04: $1.40 per share

- 2026-05: $1.14 per share

- 2026-06: $0.87 per share

- 2026-07: $0.54 per share

- 2026-08: $0.96 per share

- 2026-09: $0.87 per share

- 2026-10: $0.67 per share

## Annual estimated value (USD per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

[Original 10-K filing](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092547/ivvd-20251231.htm); period 2025-12-31, filed 2026-03-05.

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.